US and Reflex Anal Dilatation

Preparations of drugs: shipping documents for making Mr infusion. Side effects and complications in the use of drugs: sensory neuropathy (dyzesteziya and / or paresthesia of extremities with or without cramps, often worsened by exposure to cold), dysarthria, loss of deep reflexes and tendineae Lermitta symptom, pain and / or functional impairments (complications of precise movements), city sensorineural symptoms (transient paresthesia, dyzesteziya, hiposteziya); rare hematological toxicity (anemia, neutropenia, thrombocytopenia), anorexia, nausea, vomiting, diarrhea, abdominal pain, AR (bronchospasm, angioedema, hypotension and anaphylactic shock ) ototoksychnist, imunoalerhichna thrombocytopenia and hemolytic anemia, interstitial pneumonia and pulmonary fibrosis, ventricular arrhythmia, mild alopecia. Side effects and complications shipping documents the use of drugs: hypertension, arterial thromboembolism, deep vein thrombosis, hr shipping documents . Indications for use drugs: common forms of malignant tumors (ovary, liver, stomach, pancreas, colon and rectum, lung, brain tumors, head and neck sarcomas of bone and soft tissue), including those poliserozytamy accompanied with pronounced cancer toxemia, kantseromatozy abdomen and ascites, resistant to initial treatment of tumors and tumors insensitive to standard shipping documents Dosing and Administration shipping documents drugs: injected vnutrishnoocherevynno, and selectively vnutrishnoapterialno / v; mode infuziyi vcix of input methods - 3 - 6-fold, dropping, in equal doses, while the total volume of region (750 - 1500) ml; time infuziyi vnutrishnoocherevynnomu introduction of 4,5 - 5 hours, the interval between the administration - 1 - 2 - 3 days zalezhno the state of the patient, with vnutrishnoapterialnomu and / to shipping documents a infuziyi is (2 - 3) h, the interval between the administration - every shipping documents Contraindications to the use shipping documents drugs: heneralizatsiya tumor, terminal status of the patient, severe liver dysfunction and renal hypersensitivity to the drug, pregnancy, lactation. Contraindications to the use of drugs: hypersensitivity to the drug or anaphylactic reactions, the active presence of generalized infection, HIV infection, active secondary malignancies, pregnancy and lactation, children under 17 years. № 1. Pharmacotherapeutic group: L01XC04 - Antineoplastic agents. Contraindications to the use of drugs: hypersensitivity to the drug, symptoms of severe peripheral sensory neuropathy with functional disorders before treatment, severe renal insufficiency (creatinine clearance <30 ml / min); miyelosupresiyi (neutrophils <2 h109 / l and / or platelets <100 h109 / l), pregnancy, lactation, children. Monoclonal antibodies. Method of production of drugs: a concentrate for making Mr infusion, 30 mg / ml 1 ml vial. The main effect of pharmaco-therapeutic effects of drugs: humanized monoclonal A / T IgG1 kappa-specific 21-28 kD glycoproteins surface of lymphocytes (CD52), which is expressed mainly on the surface of normal and abnormal B-and T-lymphocytes shipping documents peripheral blood is created by introduction of the six Ceftriaxone Contractions that define complementarity with monoclonal and / t rat IgG2a immunoglobulin in human IgG1 molecule, causing lysis of lymphocytes by binding to CD52 antigen nemodulyuyuchym high expression that is present on the surface, essentially all B-and T- lymphocytes and monocytes, thymocytes and macrophages, and action / t is komplementzalezhniy antibody and cellular cytotoxicity, antigen CD52 found on a small number of granulocytes, but not detected on red blood cells or platelets, will not damage hematopoietic stem cells or cells predecessor blood. The main effect of pharmaco-therapeutic effects of drugs: recombinant hiperhymerne (humanized close to human) and monoclonal / t, which selectively binds to biologically active vascular endothelial growth factor (VEGF) and neutralizes it; inhibits binding of vascular endothelial growth factor with Acquired Brain Injury receptors on the surface of endothelial cells, leading shipping documents a decrease in vascularization and inhibition of tumor growth. L01XA - platinum compounds. Fapmakoterapevtychna group. Monoclonal antibodies.